You just read:

SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)

News provided by

SCYNEXIS, Inc.

Nov 07, 2019, 08:00 ET